Parasocialby Super Simple™

On The Pen GLP-1 News

Dave Knapp GLP-1 Industry Insider

Subscribe in Parasocial

Free on the App Store for iPhone, iPad and Mac. No subscription needed. Once it is installed, tap this link again and the show is yours. Already have it? Open in Parasocial.

About

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 0.5% of all podcasts globally, and On The Pen is a top Substack best-seller.

Also on

Recent episodes

  • Ozempic & Zepbound Are Changing America in Ways Nobody ExpectedOct 7, 2026 · 25 min
  • They TRIPLED Wegovy Dose, Does it Beat Zepbound?Oct 1, 2026 · 31 min
  • Retatrutide in Court, Compound GLP-1 Under FireSep 22, 2026 · 30 min
  • 17% Weight Loss in 16 Weeks… Is This Better Than Retatrutide?Sep 15, 2026 · 30 min
  • GLP-1 for 6 Year Olds? Here’s What the Trial Actually FoundSep 8, 2026 · 26 min
  • We’re Solving Obesity. Now Who Pays for It?Sep 2, 2026 · 25 min
  • GLP-1 Coverage Is COLLAPSING in 2027Aug 26, 2026 · 35 min
  • $50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”Aug 18, 2026 · 45 min
  • 200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard StudyAug 12, 2026 · 31 min
  • Eli Lilly Earnings Call Recap: Retatrutide NewsAug 7, 2026 · 60 min

Website · RSS feed

On The Pen GLP-1 News | Parasocial